Low Hemolytic Antimicrobial Peptide Sequence Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antimicrobial peptides exhibit broad-spectrum activity but often have high hemolytic activity, limiting their pharmaceutical potential due to potential harm to erythrocytes.
Innovation Solution
Development of low hemolytic antimicrobial peptides with specific amino acid sequences, such as (P1)M(nA1X1X2)N(P2)X, which are tryptophan-rich and can be modified for improved activity and toxicity, suitable for broad-spectrum resistance against bacteria, protozoa, fungi, and viruses, and can be used in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antimicrobial peptides are used to achieve broad-spectrum antimicrobial activity, then antimicrobial effectiveness is improved, but hemolytic activity increases causing harm to erythrocytes
Solution Approach 1:
The patent applies local quality by designing specific amino acid sequences with distinct functional regions. The peptides contain cationic residues (Arg, Lys) for membrane interaction, aromatic residues (Trp, Phe) for hydrophobic interactions, and carefully controlled hydrophobic regions. This localized functional differentiation allows the peptides to effectively target bacterial membranes while minimizing interaction with erythrocyte membranes, thus achieving high antimicrobial activity with low hemolytic activity.
Solution Approach 2:
The patent employs parameter changes by systematically optimizing amino acid composition and sequence structure. Specific parameters including the ratio of cationic to anionic residues, hydrophobicity indices, molecular weight (1-5 kDa), and amino acid sequence patterns were adjusted to achieve the desired balance between antimicrobial efficacy and reduced hemolysis. The defined formula (P1)M(nA1X1X2)N(P2)X with specific residue constraints represents controlled parameter optimization.
2Reliability
If antimicrobial peptides with high membrane activity are designed to enhance bacterial cell disruption, then antimicrobial effectiveness is improved, but hemolytic activity increases damaging human red blood cells
Solution Approach 1:
The patent applies segmentation by dividing the peptide structure into distinct functional domains represented by the formula (P1)M(nA1X1X2)N(P2)X. P1 and P2 represent basic amino acid segments for electrostatic interaction with negatively charged bacterial membranes, while A1, X1, and X2 represent aromatic and hydrophobic segments for membrane insertion and disruption. This segmented design allows selective targeting of bacterial membranes through specific sequence patterns that differentiate them from erythrocyte membranes.
Solution Approach 2:
The patent employs asymmetry in the amino acid sequence arrangement within the formula (P1)M(nA1X1X2)N(P2)X. The asymmetric distribution of cationic, aromatic, and hydrophobic residues creates an uneven charge and hydrophobicity pattern that preferentially interacts with bacterial membranes. This asymmetric structure enables the peptides to achieve effective membrane disruption against bacteria while exhibiting reduced hemolytic activity due to the specific spatial arrangement of functional groups.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides demonstrate outstanding antimicrobial activity with low hemolytic effects, making them suitable for antibiotic development and clinical use against gram-positive and gram-negative bacteria, protozoa, fungi, and viruses, while minimizing harm to human red blood cells.
Implementation Method 1
The antimicrobial peptides readily partition into phospholipid bilayers with greater than 95% of the peptides binding to lipid to compromise membrane integrity
Implementation Method 2
In bacteria, antimicrobial peptides are able to cause small, transient increases in conductance in planar lipid bilayers, thereby partially depolarizing the cytoplasmic membrane potential gradient
Data Source
AI summary
Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.